Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
229
resultados
Última actualización
14/07/2026 [07:45:00]
Resultados 25 a 50 de 229
Resumen de: US20260191956A1
The present disclosure provides compositions comprising modified immune cells or precursors thereof (e.g. T cells) comprising chimeric antigen receptors (CARs) along with modified cells comprising lipid nanoparticles (LNPs) comprising a nucleic acids encoding a truncated target antigens. Methods of treating disease (e.g. cancer) by administering said compositions to a subject in need thereof, are also provided.
Resumen de: US20260191990A1
The present invention relates to compositions for effective delivery of gene editing agents to a target cell, as well as methods of use thereof for the treatment of a disease or disorder.
Resumen de: WO2026147897A1
This invention relates to compositions, and uses and methods thereof, with therapeutic deciparticles. Described herein are deciparticle (nanoparticle) compositions composed of an amphiphilic compound complexed with an auxiliary compound such as a biologically active molecule. Deciparticles of this invention are active drugs having anti-tumor potency. This invention is also directed to amphiphilic compounds useful for making deciparticle complexes.
Resumen de: WO2026146887A1
The present invention relates to a polymeric nanoparticle for oral administration of physiologically active substances and a preparation method therefor and, more specifically, to a carrier or polymeric hydrogel for delivery of a physiologically active substance and a preparation method therefor, wherein the carrier or polymeric hydrogel comprises: polymeric micelles including a PEG-based block copolymer prepared by a reversible addition–fragmentation chain transfer (RAFT) radical polymerization method using a polymer that has a specific functional group at the chain end thereof and a boronic acid group introduced into the backbone thereof; and a physiologically active substance that can be encapsulated in the polymeric micelles, including a type 2 diabetes drug, insulin, an anti-obesity agent, a DPP-4 inhibitor, or an anticancer agent.
Resumen de: WO2026147893A2
This invention relates to compositions, and uses and methods thereof, with therapeutic deciparticles. Described herein are deciparticle (nanoparticle) compositions composed of an amphiphilic compound complexed with an auxiliary compound such as a biologically active molecule. Deciparticles of this invention are active drugs having potency for anti-tumor effects and for immunosuppression. This invention is also directed to amphiphilic compounds useful for making deciparticle complexes.
Resumen de: WO2026147896A1
This invention relates to compositions, and uses and methods thereof, with therapeutic deciparticles. Described herein are deciparticle (nanoparticle) compositions composed of an amphiphilic compound complexed with an auxiliary compound such as a biologically active molecule. Deciparticles of this invention are active drugs having potency for treating disease. A nanomedicine platform is provided for various pharmacological uses. This invention is also directed to amphiphilic compounds useful for making deciparticle complexes.
Resumen de: WO2026147902A1
This invention relates to therapeutic deciparticle compositions and uses and methods thereof. Described herein are deciparticle (nanoparticle) compositions composed of an amphiphilic compound complexed with auxiliary compounds such as a biologically active molecules. This invention further relates to methods for treating cancer with deciparticle compositions.
Resumen de: WO2026147899A1
This invention relates to compositions, and uses and methods thereof, with therapeutic deciparticles. Described herein are deciparticle (nanoparticle) compositions composed of an amphiphilic compound complexed with a therapeutic agent. This invention further relates to methods for treating cancer, or providing immunosuppression for transplantation, or for treating severe rheumatoid arthritis with deciparticle compositions.
Resumen de: WO2026147900A1
This invention provides methods for making therapeutic deciparticle compositions and drug products thereof. Described herein are deciparticle compositions which can be composed of an amphiphilic compound complexed with an auxiliary compound such as a biologically active molecule. Deciparticle (nanoparticle) compositions of this invention have potency for pharmacological effects for treating disease.
Resumen de: US20260191778A1
0000 Lipid nanoparticles (LNPs) containing particular cationic ionizable lipids with a biologically active polynucleotides (e.g., RNAs) are provided. In some aspects, the LNP complexes are provided as aerosols and/or dry powders, such as for delivery to the lungs. Methods of making and using such compositions are provided.
Resumen de: US20260191902A1
Zinc-based nanoclusters having: a zinc-based metal core covered over its entire surface with a mixed layer including histidine, acetate ions, and ascorbate ions, the metal core composed of zinc or a mixture of 80 to 99.99 wt % zinc and 0.01 to 20 wt % selenium; a spherical shape; a hydrodynamic diameter of 0.6 to 2.0 nm; a metal core diameter of 0.5 to 1.5 nm; a stability of 5 to 20 weeks in liquid form stored at 4° C.; a stability of at least 12 months in dry form stored at 4° C. under nitrogen; a shoulder in the UV-visible spectrum at 300±15 nm and a fluorescence spectrum with excitation wavelengths of 364±15 nm and emission wavelengths of 415±15 nm. Also, a method of preparing the zinc-based nanoclusters and their use for combating zinc deficiencies or zinc and selenium deficiencies.
Resumen de: WO2026147892A1
This invention relates to compositions, and uses and methods thereof, with therapeutic deciparticles. Described herein are deciparticle (nanoparticle) compositions composed of an amphiphilic compound complexed with an auxiliary compound such as a biologically active molecule. Deciparticles of this invention are active drugs having potency for anti-tumor effects. This invention is also directed to amphiphilic compounds useful for making deciparticle complexes.
Resumen de: WO2026147895A1
This invention relates to compositions, and uses and methods thereof, with therapeutic deciparticles. Described herein are deciparticle (nanoparticle) compositions composed of an amphiphilic compound complexed with an auxiliary compound such as a biologically active molecule. Deciparticles of this invention are active drugs having anti-cancer potency. This invention is also directed to amphiphilic compounds useful for making deciparticle complexes.
Resumen de: WO2026147683A1
Disclosed herein are biodegradable, ionizable lipids having a thioglycerol moiety, which are useful in forming lipid nanoparticles for delivery of therapeutic payloads, including nucleic acids. Pharmaceutical compositions and methods of using the same are also provided.
Resumen de: WO2026146128A1
The present invention relates to nanostructured lipid carriers (NLC) comprising vitamin D3 compounds, pharmaceutical compositions comprising the NLCs, and to their use in the treatment or prevention of diseases related to vitamin D deficiency, such as vitamin D deficiency, demineralization such as hypocalcemia and hypophosphatemia, renal osteodystrophy, rickets, osteoporosis, osteopenia, osteoarthritis, osteoarthrosis, osteomalacia, hypoparathyroidism, and inflammatory bowel disease, and to their process of manufacture.
Resumen de: WO2026147080A1
The present invention provides an amine-based cyclolipid compound of chemical formula 1, and a pharmaceutically acceptable salt thereof. The amine-based cyclolipid compound according to the present invention is used as an ionizable lipid that is a component of lipid nanoparticles for delivering nucleic acids.
Resumen de: WO2026148182A1
The present invention relates to a coacervate composition of an alpha-helical antimicrobial peptide. In particular, the coacervate composition of the present invention exhibits reduced toxicity and increased dose tolerance compared to free alpha-helical antimicrobial peptide. The present invention also provides a method for preparing the coacervate composition, and a method for delivering an alpha-helical antimicrobial peptide and a method for treating bacterial infection using the coacervate composition. The present invention further provides a pharmaceutical composition preparing from the coacervate composition, and use of the coacervate composition for manufacturing a medicament for treating bacterial infection. In particular, the bacterial infection is caused by antibiotic resistant bacteria.
Resumen de: WO2026147427A1
The invention relates to a soy lecithin-based encapsulated curcumin, the production method of this soy lecithin-based encapsulated curcumin, and its use in the treatment of prostate cancer. In the invention, the soy lecithin-based encapsulated curcumin produces a stronger toxic effect on cancer cells compared to free curcumin. Cellular uptake studies also show that the soy lecithin-based encapsulated curcumin exhibits five times higher accumulation in cancer cells than the free form. At the same time, according to the results of the animal experiment conducted on the 22Rv1 xenograft prostate model, the mean tumour volumes in the group treated with SLKUR were found to be approximately one-tenth lower compared to the control group. These results demonstrate that SLKUR possesses a higher antitumour effect compared to KUR. The invention provides a new formulation comprising 100% natural SLKUR, which enables the use of curcumin as an anticancer agent in a water-soluble carrier with high solubility, thereby increasing the absorption of curcumin.
Resumen de: AU2025207205A1
The present application relates to nanoparticles comprising (a) an amphiphilic polymer; (b) a first lipid comprising a polar head group and a non-polar tail group; and (c) a peptide comprising a T cell epitope. Also disclosed are populations of said nanoparticles, processes for manufacturing said nanoparticles, precursors for manufacturing said nanoparticles, pharmaceutical compositions of said nanoparticles, and methods of treating a disease or disorder comprising administering said nanoparticles to a subject.
Resumen de: US20260191793A1
Disclosed are exosomes comprising a Na+ taurocholate co-transporting polypeptide (NTCP) binding motif, such as HBV preS1 peptide (PSIP). Disclosed are methods of making exosomes that have been engineered to express a heterologous binding motif on the surface of the exosome, wherein the heterologous binding motif is a NTCP binding motif. Disclosed are methods of treating a subject infected with hepatitis B virus (HBV) comprising administering to the subject a therapeutically effective amount of an exosome, wherein the exosome comprises a NTCP binding motif and a therapeutic agent, thereby treating the HBV infection or any other liver diseases including liver cancer in the subject.
Resumen de: US20260191969A1
0000 The present invention provides a composition for use in attenuating skin barrier, the composition containing an anionic long-chain lipid (in particular, a long-chain fatty acid). The present invention provides a dispersion in which complexes (e.g., solid complexes) each containing a cationic long-chain lipid, an anionic long-chain lipid, and a drug are dispersed.
Resumen de: WO2026145659A1
An mRNA pharmaceutical composition for preventing and treating tuberculosis and a use thereof. The mRNA pharmaceutical composition comprises: an mRNA molecule encoding a Mycobacterium tuberculosis antigen, and a pharmaceutically acceptable adjuvant. The Mycobacterium tuberculosis antigen comprises the following antigen components: at least one Mycobacterium tuberculosis early secreted antigen or an immunologically active fragment thereof; at least one Mycobacterium tuberculosis PE/PPE family antigen or an immunologically active fragment thereof; and a Mycobacterium tuberculosis latency-associated antigen Rv2029c or an immunologically active fragment thereof. The mRNA pharmaceutical composition does not comprise or further comprises an mRNA molecule encoding a cytokine. The pharmaceutical composition is used for preparing a tuberculosis vaccine, can be used as a preventive vaccine for preventing latency reactivation, can also be used as a therapeutic drug for treating active tuberculosis, and has a significant inhibitory effect on Mycobacterium tuberculosis.
Resumen de: WO2026147352A1
The present disclosure concerns use of a nanocapsule for thermal regulation of hair, scalp, and/or skin, comprising a step of contacting the nanocapsule with the hair, scalp, and/or skin; wherein the nanocapsule comprises a shell and a core; wherein the core comprises a phase change material configured to absorb heat from the hair, scalp, skin and/or an environment adjacent to the hair, scalp, and/or skin. The present disclosure also concerns a method of cooling hair, scalp and/or skin.
Resumen de: WO2026148310A1
Disclosed are compounds and compositions that preferentially target cancer cells with a warhead that comprises a chemotherapeutic agent releasably bound to a targeting agent where the chemotherapeutic agent is released upon cellular absorption. Also disclosed are methods of use.
Nº publicación: US20260193175A1 09/07/2026
Solicitante:
SOUTH CHINA UNIV OF TECHNOLOGY [CN]
South China University of Technology
Resumen de: US20260193175A1
0000 The present disclosure discloses an alkanolamine multi-tailed lipid, a preparation method therefor, and a use thereof. The structural formulas of the lipid such as compound of Formula I, compound of Formula II or their stereoisomers, their tautomers, or their pharmaceutically acceptable salts:
0000
0000 The ionizable lipid compound of the present disclosure maintains nanoparticle stability and delivery efficiency while simplifying LNP composition, offering advantages of high efficacy and low toxicity. Even under neutral conditions, the ionizable lipid compound can still adsorb mRNA through hydrogen bonding and van der Waals interactions. The synthesis method for the diethanolamine multi-tailed ionizable lipid of the present disclosure is straightforward. The ionizable lipid can be prepared on a large scale via a few addition reaction steps, which is convenient for high-throughput material screening.
BOPI
Sede Electrónica
